Skip to main content
Glama

Gdc

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark this as read-only, idempotent, and non-destructive, and the description goes well beyond them. It discloses internal cascading lookups, graceful degradation when GLEIF/OpenFIGI are unavailable, explicit representation of unresolved identifiers, and how ISINs resolve to legal entities. This gives the agent accurate expectations about behavior and failure modes.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and information-rich, with the core purpose and usage front-loaded before examples. It is longer than strictly necessary due to nested parentheticals and multiple sources, but every major clause adds operational value. The structure by supported types and graceful-degradation notes is logical.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema and two required parameters, the description covers what an agent needs: accepted inputs, returned identifiers, source attribution, unresolved behavior, ISIN handling, and degradation behavior. It is sufficiently complete for correct selection and invocation without additional probing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although the schema already documents both parameters, the description substantially enriches their semantics. It gives concrete examples (AAPL, 0000320193, 'ozempic'), explains what ISIN inputs do, and warns that security-class words like 'revenue bonds' will not match. This is well beyond the schema's baseline coverage.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description gives a specific verb ('resolve') and resource ('user-spoken NAME to canonical/official identifiers'), with a clear list of supported types and concrete examples. It distinguishes this tool from other lookup tools by making the input (name) and output (identifiers) explicit. An agent can immediately tell what the tool accomplishes.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly instructs 'Use FIRST whenever you have a name but need an ID', providing strong usage guidance. It also covers accepted input forms (ticker, CIK, ISIN, company name, drug brand/generic name), but it does not name specific alternatives or say when not to use this tool versus a sibling like entity_profile.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Gdc toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4/5.0
Disambiguation4/5

Most tools have distinct purposes, but ask_pipeworx and ask_pipeworx_grounded overlap in routing (differ only in answer mode), and the multiple Polymarket tools (bet_research, polymarket_arbitrage, polymarket_edges, polymarket_kalshi_spread) could cause confusion without careful reading of descriptions.

Naming Consistency3/5

Naming mix of verb-first (ask_pipeworx, compare_entities) and noun-first (entity_profile, recent_changes) patterns. Most use snake_case consistently, but the pattern is not uniform—some tools are commands, others are descriptors. Notable deviations like 'pipeworx_feedback' and 'pmc' are missing here but the sample shows inconsistency.

Tool Count3/5

30 tools is on the high side, but the server covers a broad domain (data lookup, betting, AI, genomics, memory). Some tools could be merged (e.g., ask_pipeworx and its grounded variant), and the betting subdomain feels over-instrumented. The count is borderline between appropriate and heavy.

Completeness3/5

The server provides a wide range of operations for its diverse domains, but gaps exist: the genomics tools only offer basic metadata search (no download/analysis), and the betting tools lack historical data or backtesting. It covers common patterns but with notable omissions for a cohesive experience.

Resources